Rafael (RFL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for January 9, 2025, with voting on director elections, auditor ratification, and an equity plan amendment.
Record date for voting is November 12, 2024; shareholders may vote in person or by proxy.
Proxy materials and annual report are available online; meeting to be held at company headquarters in Newark, NJ.
Voting matters and shareholder proposals
Election of five directors for one-year terms.
Ratification of CohnReznick LLP as independent auditor for fiscal year ending July 31, 2025.
Approval of amendment to 2021 Equity Incentive Plan to increase Class B Common Stock available for awards by 750,000 shares.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Board consists of five directors, majority of whom are independent per NYSE standards.
Committees: Audit, Compensation, Corporate Governance, and Nominating, all with independent members.
Board and committees met regularly in fiscal 2024; all directors attended at least 75% of meetings.
Lead Independent Director role in place; risk oversight distributed among committees.
Director selection process considers diversity, experience, and shareholder recommendations.
Latest events from Rafael
- Net loss widened on higher R&D, cash at $37.8M, pivotal trial results due Q3.RFL
Q2 202616 Mar 2026 - $25M shelf offering to fund rare disease drug development and strategic initiatives.RFL
Registration Filing16 Dec 2025 - Shelf registration allows flexible capital raising with robust governance and indemnification.RFL
Registration Filing16 Dec 2025 - Net loss rose to $9.8M on higher R&D costs, with $45.5M in cash and Phase 3 trial ongoing.RFL
Q1 202612 Dec 2025 - Annual meeting to elect directors, ratify auditor, and expand equity plan share pool.RFL
Proxy Filing18 Nov 2025 - Phase 3 trial progress and $25M rights offering drive improved financial outlook.RFL
Q4 202529 Oct 2025 - Q1 FY2025 net loss rose to $9.0M as focus shifts to Trappsol Cyclo™ post-merger.RFL
Q1 202513 Jun 2025 - FY2024 net loss reached $34.4M, with a major IPR&D charge and focus shifting to the Cyclo merger.RFL
Q4 202413 Jun 2025 - Net loss narrowed, cash strengthened, and pivotal Phase 3 trial results are imminent.RFL
Q3 202511 Jun 2025